摘要 |
This patent is an evolution of U.S. Pat. No. 4,216,770 named "sickle cell therapeutic treatment". That patent is one in which blood is taken out of the subject and treated with anti-sickling agents which are then washed out. In this application blood is removed from a subject and instead filtered to remove diseased cells. The option to introduce anti-sickling agents is then left as a possible option. The filtered cells are then returned to the subject. This technology is superior to other treatments since it can help end sickle cell crises before permanent damage it done. Instead of sickled cells breaking down within the body where they compound damage, they are removed before they can cause problems. More deformable and useful blood cells are retained in the circulation.
|